An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity

  • Yu Yang
  • , Fan Yang
  • , Zeyu Xiong
  • , Yan Yan
  • , Xinmen Wang
  • , Michiya Nishino
  • , Dragan Mirkovic
  • , Justin Nguyen
  • , Hong Wang
  • , Xiao Feng Yang

Research output: Contribution to journalArticlepeer-review

175 Scopus citations

Abstract

Bcl-xL plays a critical role in maintaining cell survival. However, the relationship between the potential interaction of Bcl-xL with other cytosolic proteins and the regulation of cell survival remains incompletely defined. We have identified translationally controlled tumor protein (TCTP), a multifunctional protein, as a novel antiapoptotic Bcl-xL-interacting protein. TCTP interacted in vivo and in vitro with Bcl-xL, and their sites have been mapped to an N-terminal region of TCTP and the Bcl-2 homology domain 3 of Bcl-xL. Consistent with a role in maintaining T-cell survival during activation, TCTP was significantly upregulated in murine T cells activated by T-cell antigen receptor (TCR) ligation and CD28 costimulation, which was correlated with the upregulation of Bcl-xL in activated T cells. Moreover, downregulation of TCTP expression by antisense technology in T cells results in the increase of T-cell apoptosis. Furthermore, the N-terminal region of TCTP was required for its ability to inhibit apoptosis. In conclusion, this study has demonstrated that an N-terminal region of a cytosolic protein, TCTP, is required for its binding to Bcl-xL and for its antiapoptotic activity.

Original languageEnglish
Pages (from-to)4778-4788
Number of pages11
JournalOncogene
Volume24
Issue number30
DOIs
StatePublished - Jul 14 2005

Keywords

  • Apoptosis
  • Bcl-xL
  • Protein interaction
  • TCTP

Fingerprint

Dive into the research topics of 'An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity'. Together they form a unique fingerprint.

Cite this